Prana looks at Huntington’s
Tuesday, 02 December, 2008
Melbourne company Prana Biotechnology is investigating the potential of its lead compound, PBT2, in Huntington’s disease.
PBT2, a metal-protein-attenuating compound (MPAC), is in Phase IIb clinical trials for Alzheimer’s disease.
The compound reduces the toxic metal-protein interaction seen in both neurological diseases and has a neuroprotective effect.
Chairman of Prana’s R&D advisory board, Professor Jeffery Cummings, told the company’s AGM that a report commissioned from an independent clinical research group recommended that Prana proceed to clinical trials.
Prana is in confidential talks with several pharma companies with a view to licensing PBT2, the company said.
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
